Antimicrobial Screening Results

Table S1
Antifungal screening results for ILs 19-22 (MIC, IC80 or IC50). Klebsiella pneumoniae HK11750/08, KP-E: Klebsiella pneumoniae ESBL HK14368/08.
Materials and Methods
All chemicals were purchased at Sigma-Aldrich. Pyridine (99.8 %), bromoacetyl bromide (≥98 %), thionyl chloride (≥99 %), thionyl bromide (97 %) were used without further purification.
1-methylimidazole (99 %) was distilled before use and all organic solvents were also dried before use. All NMR spectra were recorded in deuterated chloroform (99.8 % D) on a Bruker 400 MHz spectrometer with chemical shifts reported in parts per million (ppm) relative to the internal standard (TMS) and coupling constants (J) are reported in Hertz (Hz). All IR analysis was carried out on a Perkin Elmer FT-IR spectrum GX spectrometer with a Thermo Scientific iD5 Diamond ATR attachment. All melting points (uncorrected) were obtained using a Stuart 6 were prepared according to modified versions of the literature methods described below. 1-(2-Ethoxy-2-oxo-1-phenylethyl)pyridin-1-ium bromide (4), 7 butyl 2-hydroxy-2-phenylacetate (13) 8 and ethyl 2-bromo-2-phenylacetate (16) 9 were prepared using new procedures described below.
Antifungal Activity Screening -Charles University
In vitro antifungal activities of the compounds were evaluated on a panel of four ATCC strains (Table 3) . Each well was inoculated with 5 μL of bacterial culture. Wells containing medium only were used as blanks and wells containing medium and culture only were used as positive controls.
All the toxicity tests were carried out in triplicate. The microplates were incubated overnight S7 at 30 °C. The presence or absence of growth was determined by measuring the optical density of the wells at a wavelength of 405 nm using a plate reader. The IC50 values were determined as the concentration or range of concentrations that caused a 50 % reduction in growth.
Closed Bottle Biodegradation Test (CBT) Procedure
The CBT measures aerobic biodegradability and is one of six test methods described in the OECD Guidelines for Testing of Chemicals 11 used to evaluate readily biodegradability of organic compounds. The test was undertaken at 20 ± 1 °C in the dark in the laboratories of the Institute of Sustainable and Environmental Chemistry at Leuphana University Lüneburg as described in details elsewhere. 12 It consisted of four different test series all run in duplicate.
The blank series contained only mineral medium and inoculum. The test series contained additionally the IL as the only organic carbon available for the microorganisms during the test.
The quality control contained, in addition to the blank, the readily biodegradable compound sodium acetate, which was used to monitor the activity of the microorganisms. The toxicity control contained both the IL and the sodium acetate in addition to the mineral medium ad inoculum. The amount of IL and sodium acetate corresponded to a theoretical oxygen demand According to the guidelines, for the test to be valid the reference compound sodium acetate needs to degrade by at least 60 % within 14 days. Toxicity towards the test microorganisms was evaluated by comparing the oxygen consumption of the toxicity control to the predicted level of oxygen consumption, calculated from the oxygen consumption of the quality control and the test control. A compound is labelled toxic if the difference between the predicted oxygen consumption and the measured oxygen consumption exceeds 25 %.
11
The biochemical oxygen demand (BOD) was measured in accordance with international standard methods 13 using sensor spots in the bottles and an oxygen electrode (Oxi 196 with EO 196-1.5 WTW Weilheim, Germany) 14 at a day 0, 0 (after 3 h), 1, 7, 14, 21 and 28.
Synthetic Procedures
General Procedure A: Preparation of Mandelate Bromide ILs (1-10)
3-(2-Methoxy-2-oxo-1-phenylethyl)-1-methyl-1H-imidazol-3-ium bromide (1)
A flask was charged with methyl 2-bromo-2-phenylacetate (15) 
1-(2-Methoxy-2-oxo-1-phenylethyl)pyridin-1-ium bromide (2)
The title compound (2) was synthesised from methyl 2-bromo-2-phenylacetate (15) 
3-(2-Ethoxy-2-oxo-1-phenylethyl)-1-methyl-1H-imidazol-3-ium bromide (3)
The title compound (3) was synthesised from ethyl 2-bromo-2- 
3-(2-Butoxy-2-oxo-1-phenylethyl)-1-methyl-1H-imidazol-3-ium bromide (5)
The title compound (5) was synthesised from butyl 2-bromo- 
1-(2-Butoxy-2-oxo-1-phenylethyl)pyridin-1-ium bromide (6)
The title compound (6) was synthesised from butyl 2-bromo-2-phenylacetate (17) 
1-(2-Butoxy-2-oxo-1-phenylethyl)-3-methoxypyridin-1-ium bromide (7)
The title compound (7) was synthesised from butyl 2-bromo-2-phenylacetate (17) 
1-(2-Butoxy-2-oxo-1-phenylethyl)-3-(ethoxycarbonyl)pyridin-1-ium bromide (8)
The title compound (8) 
3-(2-(Butylamino)-2-oxo-1-phenylethyl)-1-methyl-1H-imidazol-3-ium bromide (9)
The title compound (9) was synthesised from 2-bromo-N-butyl-2-phenylacetamide (18 
1-(2-(Butylamino)-2-oxo-1-phenylethyl)pyridin-1-ium bromide (10)
The title compound (10) was synthesised from 2-bromo-N-butyl-2-phenylacetamide (18) (5.00 g, 18.5 mmol), diethyl ether (5 mL) and pyridine (1.42 mL, 17.6 mmol), according to the general procedure A. 
Procedure B: Preparation of Mandelate Esters (11-13) Methyl 2-hydroxy-2-phenylacetate (11) 3,15
A flask was charged with mandelic acid (10.10 g, 66.38 mmol) and methanol (50 mL), under N2. Whilst stirring and cooling in an ice bath (0 °C), thionyl chloride (2.40 mL, 33.1 mmol) was added dropwise and the reaction was stirred at rt for 4 h. TLC confirmed reaction completion.
N2 was bubbled through the reaction for 1 h. The solvent was removed, deionised water (25 mL) was added and the product extracted with ethyl acetate (3 × 25 mL). The combined organic extracts were washed with saturated aqueous sodium bicarbonate (20 mL), dried over Butyl 2-hydroxy-2-phenylacetate (13) 8 The title compound (13) A flask was charged with mandelic acid (50.19 g, 329.9 mmol) and methanol (300 mL), under N2. Whilst stirring and cooling in an ice bath (0 °C), acetyl chloride (24.0 mL, 336 mmol) was added dropwise and the reaction was stirred overnight at rt.
TLC confirmed reaction completion. The solvent was removed and methanol (150 mL) was added. Whilst stirring and cooling in an ice bath (0 °C), n-butylamine (130 mL, 1.32 mol) was added dropwise and the reaction was left in the fridge (< 5 °C) overnight. TLC confirmed reaction completion. The solvent was removed, DCM (250 mL) was added, and the organic phase was washed with water (3 × 100 mL) and saturated aqueous ammonium chloride (100 mL). The organic phase was dried over MgSO4, filtered and the solvent removed. The S14 product was dried under reduced pressure to give the title compound (14) A flask was charged with methyl 2-hydroxy-2-phenylacetate (11) (18.08 g, 108.8 mmol) and dry DCM (100 mL), under N2. Whilst stirring, triethylamine (22.8 mL, 163 mmol) was added. The reaction was cooled in an ice bath (0 °C), thionyl bromide (10.0 mL, 129 mmol) was added dropwise and the reaction was stirred overnight at rt. TLC confirmed reaction completion and N2 was bubbled through the reaction for 1 h. The organic phase was washed with deionised water (3 × 50 mL) and the combined aqueous phase was subsequently washed with DCM (20 mL). The combined organic phase was dried over MgSO4, filtered and the solvent removed. 
2-Bromo-N-butyl-2-phenylacetamide (18)
The title compound (18) 
Figure S1
1 H NMR spectra of IL 1 (400 MHz, CDCl3).
Figure S2
13 C NMR spectra of IL 1 (101 MHz, CDCl3).
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Figure S3
1 H NMR spectra of IL 2 (400 MHz, CDCl3).
Figure S4
13 C NMR spectra of IL 2 (101 MHz, CDCl3).
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Figure S5
1 H NMR spectra of IL 3 (400 MHz, CDCl3).
Figure S6
13 C NMR spectra of IL 3 (101 MHz, CDCl3).
Figure S7
1 H NMR spectra of IL 4 (400 MHz, CDCl3). 1 H NMR data are in agreement with the literature. 
Figure S8
13 C NMR spectra of IL 4 (101 MHz, CDCl3). 13 C NMR data are in agreement with the literature. 7 
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Figure S9
1 H NMR spectra of IL 5 (400 MHz, CDCl3).
Figure S10
13 C NMR spectra of IL 5 (101 MHz, CDCl3).
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Figure S11
1 H NMR spectra of IL 6 (400 MHz, CDCl3).
Figure S12
13 C NMR spectra of IL 6 (101 MHz, CDCl3).
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Figure S13
1 H NMR spectra of IL 7 (400 MHz, CDCl3).
Figure S14
13 C NMR spectra of IL 7 (101 MHz, CDCl3).
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Figure S15
1 H NMR spectra of IL 8 (400 MHz, CDCl3).
Figure S16
13 C NMR spectra of IL 8 (101 MHz, CDCl3).
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Figure S17
1 H NMR spectra of IL 9 (400 MHz, CDCl3).
Figure S18
13 C NMR spectra of IL 9 (101 MHz, CDCl3).
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Figure S19
1 H NMR spectra of IL 10 (400 MHz, CDCl3).
Figure S20
13 C NMR spectra of IL 10 (101 MHz, CDCl3).
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Figure S21
1 H NMR spectra of compound 17 (400 MHz, CDCl3).
Figure S22
13 C NMR spectra of compound 17 (101 MHz, CDCl3).
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Figure S23
1 H NMR spectra of compound 18 (400 MHz, CDCl3).
Figure S24
13 C NMR spectra of compound 18 (101 MHz, CDCl3).
